TWI367881B - Alpha crystalline form of strontium ranelate, a process for its preparation, and pharmaceutical compositions containing it - Google Patents

Alpha crystalline form of strontium ranelate, a process for its preparation, and pharmaceutical compositions containing it

Info

Publication number: TWI367881B
Authority: TW; Taiwan
Prior art keywords: preparation; pharmaceutical compositions; crystalline form; compositions containing; strontium ranelate
Prior art date: 2004-09-30

Application number

TW094120331A

Other languages

English (en)

Other versions

TW200610758A (en

Inventor

Stephane Horvath

Isabelle Demuynck

Gerard Damien

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-30

Filing date

2005-06-17

Publication date

2012-07-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34942420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI367881(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-06-17 Application filed by Servier Lab filed Critical Servier Lab

2006-04-01 Publication of TW200610758A publication Critical patent/TW200610758A/zh

2012-07-11 Application granted granted Critical

2012-07-11 Publication of TWI367881B publication Critical patent/TWI367881B/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Physical Education & Sports Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Fodder In General (AREA)

TW094120331A 2004-09-30 2005-06-17 Alpha crystalline form of strontium ranelate, a process for its preparation, and pharmaceutical compositions containing it TWI367881B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0410335A FR2875807B1 (fr)	2004-09-30	2004-09-30	Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (2)

Publication Number	Publication Date
TW200610758A TW200610758A (en)	2006-04-01
TWI367881B true TWI367881B (en)	2012-07-11

Family

ID=34942420

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW094120331A TWI367881B (en)	2004-09-30	2005-06-17	Alpha crystalline form of strontium ranelate, a process for its preparation, and pharmaceutical compositions containing it

Country Status (42)

Country	Link
US (2)	US7459568B2 (zh)
EP (2)	EP1642897B9 (zh)
JP (2)	JP2006104184A (zh)
KR (1)	KR100816590B1 (zh)
CN (1)	CN100391956C (zh)
AP (1)	AP1930A (zh)
AR (1)	AR049395A1 (zh)
AT (1)	ATE411308T1 (zh)
AU (1)	AU2005202718B2 (zh)
BR (1)	BRPI0502228A (zh)
CA (1)	CA2508824C (zh)
CO (1)	CO5710195A1 (zh)
CR (1)	CR7876A (zh)
CY (1)	CY1108797T1 (zh)
DE (1)	DE602005010359D1 (zh)
DK (1)	DK1642897T3 (zh)
EA (1)	EA008474B1 (zh)
EC (1)	ECSP055859A (zh)
ES (1)	ES2314593T3 (zh)
FR (1)	FR2875807B1 (zh)
GE (1)	GEP20074106B (zh)
GT (1)	GT200500130A (zh)
HK (1)	HK1086260A1 (zh)
HR (1)	HRP20080652T3 (zh)
IL (1)	IL169237A (zh)
MA (1)	MA27815A1 (zh)
MX (1)	MXPA05006407A (zh)
NO (1)	NO333948B1 (zh)
NZ (1)	NZ540802A (zh)
OA (1)	OA13013A (zh)
PA (1)	PA8638201A1 (zh)
PE (1)	PE20060364A1 (zh)
PL (1)	PL1642897T3 (zh)
PT (1)	PT1642897E (zh)
RS (1)	RS51110B (zh)
SA (1)	SA05260168B1 (zh)
SG (1)	SG121035A1 (zh)
SI (1)	SI1642897T1 (zh)
TW (1)	TWI367881B (zh)
UA (1)	UA80008C2 (zh)
WO (1)	WO2006035122A1 (zh)
ZA (1)	ZA200504937B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2875807B1 (fr) *	2004-09-30	2006-11-17	Servier Lab	Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
US20070292529A1 (en) *	2006-06-19	2007-12-20	Tabbiner Philip S	Strontium compositions and methods of treating osteoporotic conditions
US20070292535A1 (en) *	2006-06-19	2007-12-20	Tabbiner Philip S	Strontium compositions and methods of treating arthritic and or osteoporitic conditions
CN101206208B (zh) *	2006-12-19	2011-08-10	北京德众万全药物技术开发有限公司	一种用hplc法分析雷尼酸锶原料及其制剂的方法
KR20110066197A (ko)	2008-09-29	2011-06-16	라티오팜 게엠베하	스트론튬 라넬레이트의 무수물 및 수화물 형태
IT1398542B1 (it) *	2010-03-05	2013-03-01	Chemelectiva S R L	Processo per la preparazione di un polimorfo
CN102241663B (zh) *	2010-05-10	2013-02-13	山东方明药业集团股份有限公司	一种雷奈酸锶八水合物的制备方法
WO2012143932A1 (en) *	2011-04-21	2012-10-26	Shilpa Medicare Limited	Crystalline strontium ranelate form-s
CZ2011320A3 (cs)	2011-05-30	2012-12-12	Zentiva, K.S.	Stabilní krystalická forma X stroncium ranelátu
EP2530068A1 (en)	2011-05-31	2012-12-05	Lacer, S.A.	New strontium salts, synthesis and use thereof in the treatment of osteoporosis
US9301945B2 (en)	2011-07-21	2016-04-05	Emory University	Methods for treating inflammatory conditions and states, and cancers by antagonizing NF-κB activation
CN102503931A (zh) *	2011-09-20	2012-06-20	浙江华海药业股份有限公司	一种雷尼酸锶晶形h的制备方法
WO2013113319A1 (en) *	2012-01-31	2013-08-08	Pharmathen S.A.	Process for the preparation of strontium ranelate, intermediate or hydrates thereof
EP2641905A1 (en)	2012-03-23	2013-09-25	Urquima S.A.	Solid forms of strontium ranelate and processes for their preparation
US8569514B1 (en)	2012-05-17	2013-10-29	Divi's Laboratories, Ltd.	Process for the preparation of strontium ranelate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2651497B1 (fr) *	1989-09-01	1991-10-25	Adir	Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
UA41909C2 (uk)	1994-07-22	2001-10-15	Елі Ліллі Енд Компані	Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
FR2749759B1 (fr) *	1996-06-17	1999-11-26	Adir	Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
DE19642451A1 (de)	1996-10-15	1998-04-16	Merck Patent Gmbh	Aminothiophencarbonsäureamide
JP2005504818A (ja) *	2001-10-03	2005-02-17	テバファーマシューティカルインダストリーズリミティド	レボフロキサシンおよびその形態の調製
EP2272501B1 (en) *	2002-01-09	2013-03-20	Emisphere Technologies, Inc.	Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate
US7396839B2 (en) *	2002-08-06	2008-07-08	Teva Pharmaceuticals Usa, Inc.	Crystalline forms of gatifloxacin
FR2844797B1 (fr)	2002-09-24	2004-10-22	Servier Lab	Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2844795B1 (fr) *	2002-09-24	2004-10-22	Servier Lab	Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates
FR2844796A1 (fr)	2002-09-24	2004-03-26	Servier Lab	Nouveau procede de synthese industrielle du diester methylique de l'acide 5-amino-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2875807B1 (fr) *	2004-09-30	2006-11-17	Servier Lab	Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

2004
- 2004-09-30 FR FR0410335A patent/FR2875807B1/fr not_active Expired - Fee Related
2005
- 2005-05-24 PE PE2005000574A patent/PE20060364A1/es not_active Application Discontinuation
- 2005-05-26 MA MA28300A patent/MA27815A1/fr unknown
- 2005-05-27 GT GT200500130A patent/GT200500130A/es unknown
- 2005-05-30 CA CA002508824A patent/CA2508824C/fr not_active Expired - Fee Related
- 2005-05-31 AP AP2005003323A patent/AP1930A/xx active
- 2005-05-31 US US11/140,822 patent/US7459568B2/en not_active Expired - Fee Related
- 2005-06-02 OA OA1200500169A patent/OA13013A/fr unknown
- 2005-06-14 AR ARP050102423A patent/AR049395A1/es not_active Application Discontinuation
- 2005-06-15 SA SA05260168A patent/SA05260168B1/ar unknown
- 2005-06-15 MX MXPA05006407A patent/MXPA05006407A/es active IP Right Grant
- 2005-06-15 CR CR7876A patent/CR7876A/es not_active Application Discontinuation
- 2005-06-16 CN CNB2005100753929A patent/CN100391956C/zh not_active Expired - Fee Related
- 2005-06-16 EC EC2005005859A patent/ECSP055859A/es unknown
- 2005-06-16 IL IL169237A patent/IL169237A/en not_active IP Right Cessation
- 2005-06-16 CO CO05058754A patent/CO5710195A1/es not_active Application Discontinuation
- 2005-06-17 PT PT05291297T patent/PT1642897E/pt unknown
- 2005-06-17 EP EP05291297A patent/EP1642897B9/fr not_active Revoked
- 2005-06-17 EP EP08007270A patent/EP1944302A1/fr not_active Withdrawn
- 2005-06-17 JP JP2005177199A patent/JP2006104184A/ja active Pending
- 2005-06-17 WO PCT/FR2005/001515 patent/WO2006035122A1/fr active Application Filing
- 2005-06-17 AT AT05291297T patent/ATE411308T1/de active
- 2005-06-17 DK DK05291297T patent/DK1642897T3/da active
- 2005-06-17 GE GEAP20058848A patent/GEP20074106B/en unknown
- 2005-06-17 NO NO20052998A patent/NO333948B1/no not_active IP Right Cessation
- 2005-06-17 ES ES05291297T patent/ES2314593T3/es active Active
- 2005-06-17 RS RSP-2008/0506A patent/RS51110B/sr unknown
- 2005-06-17 SG SG200503938A patent/SG121035A1/en unknown
- 2005-06-17 NZ NZ540802A patent/NZ540802A/en not_active IP Right Cessation
- 2005-06-17 SI SI200530490T patent/SI1642897T1/sl unknown
- 2005-06-17 UA UAA200505970A patent/UA80008C2/uk unknown
- 2005-06-17 DE DE602005010359T patent/DE602005010359D1/de active Active
- 2005-06-17 ZA ZA200504937A patent/ZA200504937B/en unknown
- 2005-06-17 EA EA200500842A patent/EA008474B1/ru not_active IP Right Cessation
- 2005-06-17 AU AU2005202718A patent/AU2005202718B2/en not_active Ceased
- 2005-06-17 BR BRPI0502228-2A patent/BRPI0502228A/pt not_active IP Right Cessation
- 2005-06-17 PL PL05291297T patent/PL1642897T3/pl unknown
- 2005-06-17 TW TW094120331A patent/TWI367881B/zh not_active IP Right Cessation
- 2005-07-01 PA PA20058638201A patent/PA8638201A1/es unknown
- 2005-07-08 KR KR1020050061542A patent/KR100816590B1/ko not_active IP Right Cessation
2006
- 2006-05-29 HK HK06106187A patent/HK1086260A1/xx not_active IP Right Cessation
2008
- 2008-08-12 US US12/228,381 patent/US7745482B2/en not_active Expired - Fee Related
- 2008-11-19 CY CY20081101327T patent/CY1108797T1/el unknown
- 2008-12-16 HR HR20080652T patent/HRP20080652T3/xx unknown
2010
- 2010-01-07 JP JP2010001847A patent/JP2010132669A/ja active Pending

Also Published As

Publication number	Publication date
PL1642897T3 (pl)	2009-04-30
EP1642897B9 (fr)	2009-08-12
US7459568B2 (en)	2008-12-02
EP1642897B1 (fr)	2008-10-15
MA27815A1 (fr)	2006-04-03
GEP20074106B (en)	2007-05-10
CO5710195A1 (es)	2006-12-29
MXPA05006407A (es)	2006-04-05
CY1108797T1 (el)	2014-04-09
NO20052998L (no)	2006-03-31
EP1944302A1 (fr)	2008-07-16
DK1642897T3 (da)	2009-01-26
AU2005202718B2 (en)	2010-09-16
SG121035A1 (en)	2006-04-26
FR2875807A1 (fr)	2006-03-31
SI1642897T1 (sl)	2009-02-28
EP1642897A1 (fr)	2006-04-05
EA200500842A1 (ru)	2006-04-28
AP2005003323A0 (en)	2005-06-30
DE602005010359D1 (de)	2008-11-27
IL169237A (en)	2010-12-30
OA13013A (fr)	2006-11-10
US7745482B2 (en)	2010-06-29
HK1086260A1 (en)	2006-09-15
CR7876A (es)	2007-12-10
ECSP055859A (es)	2006-09-18
CN1754878A (zh)	2006-04-05
ES2314593T3 (es)	2009-03-16
NZ540802A (en)	2006-11-30
KR20060049966A (ko)	2006-05-19
SA05260168B1 (ar)	2009-02-25
AR049395A1 (es)	2006-07-26
CN100391956C (zh)	2008-06-04
CA2508824A1 (fr)	2006-03-30
TW200610758A (en)	2006-04-01
NO333948B1 (no)	2013-10-28
UA80008C2 (uk)	2007-08-10
HRP20080652T3 (en)	2009-01-31
PE20060364A1 (es)	2006-06-17
JP2010132669A (ja)	2010-06-17
AP1930A (en)	2008-12-15
KR100816590B1 (ko)	2008-03-24
GT200500130A (es)	2005-12-20
US20060069271A1 (en)	2006-03-30
JP2006104184A (ja)	2006-04-20
ZA200504937B (en)	2006-04-26
BRPI0502228A (pt)	2006-05-09
RS51110B (sr)	2010-10-31
AU2005202718A1 (en)	2006-04-13
WO2006035122A1 (fr)	2006-04-06
CA2508824C (fr)	2009-03-24
PA8638201A1 (es)	2006-05-16
FR2875807B1 (fr)	2006-11-17
US20080312314A1 (en)	2008-12-18
EA008474B1 (ru)	2007-06-29
PT1642897E (pt)	2008-11-27
NO20052998D0 (no)	2005-06-17
ATE411308T1 (de)	2008-10-15

Publication	Publication Date	Title
HK1086260A1 (en)	2006-09-15	Alpha crystalline form of strontium ranelate, a process for its preparation, and pharmaceutical compositions containing it
HK1098129A1 (en)	2007-07-13	New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it
HK1098128A1 (en)	2007-07-13	New crystalline form v of agomelatine, a process for its preparation and pharmaceutical compositions containing it
SG130112A1 (en)	2007-03-20	New crystalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it
IL173959A0 (en)	2006-07-05	?? crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
SG131857A1 (en)	2007-05-28	δD-CRYSTALLINE FORM OF IV ABRADINE HYDROCHLORIDE, A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
IL178544A (en)	2017-04-30	Crystalline form - δ of ivabradine hydrochloride, process for preparation and pharmaceutical preparations containing it
TWI315306B (en)	2009-10-01	Bd-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
ME02750B (me)	2010-05-07	Kristalni oblik gama - d iv abradin hlorhidrata, postupak njegove izrade i farmaceutske smeše koje ga sadrže
HK1096387A1 (en)	2007-06-01	ß-CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE, A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
IL179530A0 (en)	2007-05-15	Novel compounds, pharmaceutical compositions containing same and methods of use for same
SG110170A1 (en)	2005-04-28	New benzoindoline compounds, a process for their preparation and pharmaceutical compositions containing them
IL178620A0 (en)	2007-02-11	Crystalline 2-amino-3-cyanoquinoline derivatives, process of their preparation and pharmaceutical compositions containing them

Legal Events

Date	Code	Title	Description
2018-04-11	MM4A	Annulment or lapse of patent due to non-payment of fees